Alvotech Starts European Trial For High-Concentration Adalimumab

 
• By Aidan Fry

Icelandic developer Alvotech is looking to set itself apart from the pack offering biosimilar rivals to Humira by conducting a Phase III clinical trial for an alternative to AbbVie’s high-concentration 100mg/ml version of adalimumab, the world’s best-selling drug.

HeadStatue
Alvotech is studying in plaque psoriasis patients its biosimilar of AbbVie's high-concentration version of Humira • Source: Shutterstock

More from Biosimilars

More from Products